Business Wire

Eyekandy Launches Brand ‘MetaStores’ for the Metaverse

Share

Eyekandy, one of the world's leading Augmented Reality (AR) Providers for Commerce, today announced its MetaStore service for retailers and brands.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220118006141/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

This is an example of a Metastore. #endlesspossibilities (Source: eyekandy Metastore)

The service will enable retailers and brands to easily deploy custom stores and sales campaigns into the metaverse to promote or sell digital goods, such as NFT’s. Metaverse projects can be a major cost and distraction for a marketing world that is still figuring out what the metaverse is and how it can be of most benefit. Eyekandy represents a one-stop-shop for retailers and brands to test and learn all things metaverse, without having to get into the detail of how to do it successfully.

Richard Clarke, Head of Metaverse & NFT’s at Eyekandy added: “Launching successfully in the Metaverse is a complex, multilayered project. It is a very new, cutting edge technology and sales and marketing channel - we are doing the learning and experimenting on behalf of our brand and retail partners, so they don't have to. There are multiple Metaverses and multiple ways to launch. 3D asset creation, NFT’s, purchasing digital real estate, community management, content moderation, combining digital and real-world merchandise and much more, needs careful consideration, planning and execution. Brands and retailers need our support. With our heritage in 3D and AR production and syndication, this is a very organic evolution of our business.”

“Eyekandy represents a one stop shop for retailers and brands who want to experiment in the Metaverse, without huge budgets or distraction.”

The Metaverse is a network of 3D virtual worlds focused on social connection. Since Facebook’s announcement to rebrand to META in October, it has attracted the global attention of brands. Nike, Samsung, Ralph Lauren and many more have all launched Metaverse projects to sell digital merchandise in the last three months alone.

Founder Scott Lester commented: “Our founding vision has always been to change the way the world shops with AR. This is now evolving to actually changing the world we shop in. Eyekandy has invested in digital real estate across the metaverse and our ‘metastore.x’ and ‘brandstore.x’ metaverse locations will enable our partners to engage and experiment quickly and easily with us in this new digital frontier. Brands need to be where the next generation of shoppers are – they are already in the Metaverse, shopping and buying.”

About Eyekandy

We’re changing the way the world shops with Augmented Reality. Based in London and Chicago, Eyekandy is the world's leading Augmented Reality (AR) Provider for Commerce. We partner with Retailers and Brands across the world to produce engaging AR shopper experiences in-store, online and in print. Our multi award winning, global AR shopping Platform, ‘Point & Place®’, is the world’s most adopted AR shopping platform, with hundreds of retailers connected across 30+ countries.Eyekandy has won numerous industry awards as we deliver innovation in creative ways to drive sales and engagement from shoppers with immersive ways to shop and browse.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Garrett@eyekandy.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye